PR95469

ABERDEEN, Scotland and SINGAPORE, April 14, 2022 /PRNewswire=KYODO JBN/ --

- Significant milestone in the only late-stage clinical trial targeting tau

pathology of Alzheimer's

- TauRx on track to announce top line results in May

- Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's

TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease

(AD) research, has announced that the last patient has completed treatment in

the blinded phase of their late-stage clinical trial, Lucidity (NCT03446001).

This milestone means TauRx will now progress to the data cleaning and analysis

phase which enables the company to determine topline results on the safety and

efficacy of Hydromethylthionine mesylate (HMTM). The topline results are due to

be announced in May.

Professor Claude Wischik, Executive Chairman and Co-Founder, said: "AD is a

leading cause of death in the UK and one of the world's greatest unmet medical

needs. At TauRx, we've focused our efforts over the last few decades to

developing an effective treatment for this devastating disease based on

targeting the tau pathology which is the main driver of clinical dementia.

"This milestone takes us one step closer to announcing the topline results of

our potentially ground-breaking Lucidity study. We're extremely grateful to all

who are progressing the trial; the study coordinators and investigators, and

most importantly the patients who volunteered to take part."

According to AD International, around 50 million people are affected by

dementia worldwide, and in 2050 this will rise to 152 million – with AD being

the most common form.

Lucidity is the only late-stage clinical trial specifically targeting the tau

pathology of AD. Aggregation of abnormal tau is a hallmark of AD. Tau

aggregation and the formation of tau tangles disrupt neuronal function, a

process that begins years before dementia symptoms are seen. Tau pathology

correlates strongly with AD severity and the clinical decline commonly seen in

patients.

ABOUT

TauRx's mission is to discover, develop and commercialise innovative products

for the diagnosis, treatment and cure of neurodegenerative diseases caused

through protein aggregation. The company's drug research targets the misfolding

and formation of tau aggregates that form inside nerve cells in the brain,

playing a role in the disease pathology of Alzheimer's and other dementias.

Headquarters are in Singapore and primary research facilities and operations

are in Aberdeen.

https://taurx.com/

https://www.luciditytrial.com/

Source: TauRx Pharmaceuticals Ltd